Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0O3TG
|
|||
| Drug Name |
PMID25666693-Compound-136
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Cancer related pain [ICD-11: MG30; ICD-10: R52.1, R52.2] | Patented | [1] | |
| Inflammatory pain [ICD-11: MG30.42; ICD-10: R52, G89] | Patented | [1] | ||
| Neuropathic pain [ICD-11: 8E43.0] | Patented | [1] | ||
| Osteoarthritis pain [ICD-11: MG30.31] | Patented | [1] | ||
| Company |
Novartis AG
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H15Cl2N3O
|
|||
| Canonical SMILES |
CC(C)C1=NC2=C(C=CC(=C2Cl)N)C(=O)N1C3=CC=C(C=C3)Cl
|
|||
| InChI |
1S/C17H15Cl2N3O/c1-9(2)16-21-15-12(7-8-13(20)14(15)19)17(23)22(16)11-5-3-10(18)4-6-11/h3-9H,20H2,1-2H3
|
|||
| InChIKey |
KVPDVXGLZNHXJL-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Transient receptor potential cation channel V1 (TRPV1) | Target Info | Antagonist | [1] |
| Target's Patent Info | Transient receptor potential cation channel V1 (TRPV1) | Target's Patent Info | [1] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Inflammatory mediator regulation of TRP channels | ||||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Pathway Interaction Database | Trk receptor signaling mediated by the MAPK pathway | |||
| Trk receptor signaling mediated by PI3K and PLC-gamma | ||||
| Reactome | TRP channels | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.